Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease

Table 1 Demographic, clinical and biological characteristics of the study population n (%)

Characteristics	Complete responders	Partial responders	Primary non-responders	P value
	80 (63.49)	32 (25.39)	14 (11.11)
Age (yr, mean ± SD)	28.42 ± 12.85	26.65 ± 14.21	27.32 ± 13.88	0.807
Gender (%)
Male	62 (77.5)	19 (58.37)	8 (57.14)	0.082
Female	18 (22.5)	13 (40.63)	6 (42.86)
CRP levels (mg/dL, mean ± SD)
Pre-treatment (0 wk)	3.47 ± 0.85	5.62 ± 3.44	4.48 ± 2.15	< 0.0001
Post-treatment (12 wk)	1.07 ± 0.72	3.55 ± 1.49	1.61 ± 1.4	< 0.0001
δCRP levels (%)	75.27 ± 36.23	81.03 ± 32.05	63.91 ± 32.73	0.311
Disease years	8 ± 6.48	7.47 ± 5.11	8.18 ± 4.32	0.987
Infliximab dosing (mg/kg)	5	5	5	1.000
Localization (%)
Colitis	26 (32.5)	4 (12.5)	2 (14.28)	0.295
Ileocolitis	50 (62.5)	27 (84.75)	12 (85.72)
Upper gastroenteric	4 (5)	1 (2.75)	0
Behaviour (%)
Inflammatory	34 (42.5)	10 (31.25)	5 (35.71)	0.016
Stricturing	14 (17.5)	9 (28.13)	2 (14.29)
Penetrating	32 (40)	13 (40.62)	7 (50)

Table 2 Distribution of genotypes in patients and controls n (%)

Genotype	Complete responders (n = 80)	Partial responders (n = 32)	P value; OR (95%CI)	Non-responders (n = 14)	P value; OR (95%CI)
rs1568885
AA	57 (71.25)	14 (43.75)	1.0 (reference)	4 (28.57)	1.0 (reference)
AT	21 (26.25)	14 (43.75)	0.035; 2.71 (1.11-6.64)	7 (50)	0.032; 4.75 (1.26-17.9)
TT	2 (2.5)	4 (12.5)	0.024; 8.14 (1.3549.05)	3 (21.43)	0.007; 21.37 (2.73-167.2)
rs1813443
GG	46 (57.5)	10 (31.25)	1.0 (reference)	4 (28.57)	1.0 (reference)
GC	28 (35)	14 (43.75)	0.09; 2.3 (0.9-5.87)	4 (28.57)	0.7; 1.64 (0.38-7.1)
CC	6 (7.5)	8 (25)	0.005; 6.13 (1.74-21.63)	6 (42.86)	0.002; 11.5 (2.5-52.84)
rs4411591
GG	54 (67.5)	17 (53.12)	1.0 (reference)	10 (71.43)	1.0 (reference)
GA	24 (30)	12 (37.5)	0.34; 1.58 (0.66-3.84)	4 (28.57)	1; 0.9 (0.26-3.16)
AA	2 (2.5)	3 (9.37)	0.11; 4.76 (0.73-30.94)	0	1; 1.04 (0.05-23.23)